The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Imbalance of the renin–angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?
Abstract
Objective: We evaluated the influence of the renin–angiotensin system (RAS) on intestinal inflammation and fibrosis. Design: Cultured human colonic myofibroblast proliferation and collagen secretion were assessed following treatment with angiotensin (Ang) II and Ang (1–7), their receptor antagonists candesartan and A779, and the ACE inhibitor captopril. Circulating and intestinal RAS components were evaluated in patients with and without IBD. Disease outcomes in patients with IBD treated with ACE inhibitors and angiotensin receptor blockers (ARBs) were assessed in retrospective studies. Results: Human colonic myofibroblast proliferation was reduced by Ang (1–7) in a dose-dependent manner (p<0.05). Ang II marginally but not significantly increased proliferation, an effect reversed by candesartan (p<0.001). Colonic myofibroblast collagen secretion was reduced by Ang (1–7) (p<0.05) and captopril (p<0.001), and was increased by Ang II (p<0.001). Patients with IBD had higher circulating renin (mean 25.4 vs 18.6 mIU/L, p=0.026) and ACE2:ACE ratio (mean 0.92 vs 0.69, p=0.015) than controls without IBD. RAS gene transcripts and peptides were identified in healthy and diseased bowels. Colonic mucosal Masson’s trichrome staining correlated with Ang II (r=0.346, p=0.010) and inversely with ACE2 activity (r=−0.373, p=0.006). Patients with IBD who required surgery (1/37 vs 12/75, p=0.034) and hospitalisation (0/34 vs 8/68, p=0.049) over 2 years were less often treated with ACE inhibitors and ARBs than patients not requiring surgery or hospitalisation. Conclusions: The RAS mediates fibrosis in human cell cultures, is expressed in the intestine and perturbed in intestinal inflammation, and agents targeting this system are associated with improved disease outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation
Hashimoto, T., Perlot, T., Rehman, A., Trichereau, J., Ishiguro, H., Paolino, M., Sigl, V., Hanada, T., Hanada, R., Lipinski, S., et al. (2012) · Nature · doi:10.1038/nature11228 · Cited by 1,271
Major congenital malformations after first-trimester exposure to ACE inhibitors
Cooper, W. O., Hernandez-Diaz, S., Arbogast, P. G., Dudley, J. A., Dyer, S., Gideon, P. S., Hall, K., & Ray, W. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055202 · Cited by 1,192
Cited by
Bourgonje, A. R., Abdulle, A. E., Timens, W., Hillebrands, J., Navis, G. J., Gordijn, S. J., Bolling, M. C., Dijkstra, G., Voors, A. A., Osterhaus, A. D., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5471 · Cited by 1,081
Gastrointestinal symptoms associated with COVID-19: impact on the gut microbiome
Villapol, S. (2020) · Translational Research · doi:10.1016/j.trsl.2020.08.004 · Cited by 343
COVID-19 and immunomodulation in IBD
Neurath, M. F. (2020) · Gut · doi:10.1136/gutjnl-2020-321269 · Cited by 302
Metadata
- Authors
- Garg, M., Royce, S. G., Tikellis, C., Shallue, C., Batu, D., Velkoska, E., Burrell, L. M., Patel, S. K., Beswick, L., Jackson, A., Britto, K., Lukies, M., Sluka, P., Wardan, H., Hirokawa, Y., Tan, C. W., Faux, M., Burgess, A. W., Hosking, P., Monagle, S., Thomas, M., Gibson, P. R., & Lubel, J.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2019-08-13
- Volume
- 69
- Issue
- 5
- Pages
- 841-851
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2968897107
- Cited by
- 210
- References
- 2
- FWCI
- 18.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Imbalance of the renin–angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target? https://app.cochat.ai/papers/10.1136/gutjnl-2019-318512
- The paper
- Garg, M., Royce, S. G., Tikellis, C., Shallue, C., Batu, D., Velkoska, E., Burrell, L. M., Patel, S. K., Beswick, L., Jackson, A., Britto, K., Lukies, M., Sluka, P., Wardan, H., Hirokawa, Y., Tan, C. W., Faux, M., Burgess, A. W., Hosking, P., . . . Lubel, J. (2020). Imbalance of the renin–angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target? Gut. https://doi.org/10.1136/gutjnl-2019-318512
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.